5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight
The U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national drug shortage list, the Fifth Circuit...To view the full article, register now.
Already a subscriber? Click here to view full article